Mendus

Mendus has initiated the Phase Ib DIVA trial, marking the first clinical evaluation of vididencel in combination with venetoclax and azacitidine (Ven+Aza) in newly diagnosed acute myeloid leukaemia (AML) patients considered unfit for intensive induction...

Mendus has initiated the Phase Ib DIVA trial, evaluating vididencel in combination with venetoclax and azacitidine (Ven+Aza) in newly diagnosed acute myeloid leukaemia (AML) patients with measurable residual disease (MRD) who are considered unfit for...

Mendus is drawing SEK16.5m under the second tranche of its SEK50m loan facility with Fenja Capital, taking total drawings to SEK46.5m, while the remaining SEK3.5m commitment will be cancelled. The parties have also agreed to extend the facility’s maturity...